The quest to predict Alzheimer’s disease is shifting focus, moving beyond simply identifying the presence of the disease to anticipating when symptoms might emerge. A new study, published earlier this month in Nature Medicine, suggests a blood test measuring levels of the tau protein could offer a window into that timeline, potentially years before cognitive decline becomes apparent. This research builds on a growing understanding of tau’s role in Alzheimer’s, a protein long recognized as a key component alongside amyloid plaques in the development of the disease.
For decades, the primary focus in Alzheimer’s research centered on amyloid plaques – abnormal clumps of protein that accumulate in the brain. While the presence of these plaques is a hallmark of the disease, recent clinical trials targeting amyloid have yielded underwhelming results, prompting scientists to re-evaluate the underlying mechanisms at play. Researchers are now increasingly focused on tau, specifically the formation of neurofibrillary tangles, which are closely linked to neuronal damage and cognitive decline. As Irina Skylar-Scott, MD, a clinical assistant professor of memory disorders at Stanford Medicine, noted in a 2025 dispatch, tau is what neurofibrillary tangles are composed of.
The Nature Medicine study explored the potential of a blood-based biomarker – the ratio of phosphorylated to non-phosphorylated tau at position 217, referred to as “%p-tau217” – to predict the onset of Alzheimer’s symptoms. Researchers found that this ratio could forecast symptom onset within three to four years. While the authors acknowledge this timeframe may limit its immediate use for individual medical decisions, they believe it holds significant promise for large-scale studies and tracking disease progression within populations.
The appeal of a blood test lies in its accessibility and relative simplicity compared to current diagnostic methods. Current methods for detecting tau often rely on positron emission tomography (PET) scans, which are expensive, require specialized equipment, and aren’t widely available. As Suzanne Schindler of Washington University School of Medicine explained to Nature, analyzing a blood sample is a far less resource-intensive approach. This could broaden access to early detection and potentially accelerate research efforts.
However, experts caution against interpreting these findings as the arrival of a definitive, all-purpose Alzheimer’s blood test. Schindler emphasized to Nature that, at this stage, she does “not recommend that any cognitively unimpaired individuals have any Alzheimer’s disease biomarker test.” The current research suggests the test is more useful for predicting the *timing* of symptom onset in individuals already considered at risk, rather than identifying those who will inevitably develop the disease.
The development of such a test isn’t simply about identifying a biomarker; it’s about improving our understanding of the complex cascade of events that lead to Alzheimer’s. The ability to predict when symptoms might appear could be invaluable for designing and evaluating preventative therapies. If researchers can identify individuals at high risk years before symptoms manifest, they may have a greater opportunity to intervene and slow or even halt the disease’s progression.
The research also highlights the evolving landscape of Alzheimer’s diagnostics. Traditional approaches have focused on identifying the disease *after* symptoms have appeared. The focus is now shifting towards proactive identification of risk and early intervention. This shift is driven by the recognition that Alzheimer’s disease begins to develop in the brain years, even decades, before clinical symptoms grow noticeable.
The next steps in this research will involve validating these findings in larger, more diverse populations. Researchers will also need to refine the accuracy of the %p-tau217 biomarker and determine the optimal cutoff levels for predicting symptom onset. Further studies are planned to explore the potential of combining this blood test with other biomarkers to create a more comprehensive risk assessment tool. The ongoing clinical trial at Stanford Medicine, investigating drugs that impede the formation of neurofibrillary tangles, will also provide valuable insights into the disease’s progression and potential therapeutic targets.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have thoughts on this developing area of Alzheimer’s research? Share your comments below, and consider sharing this article with others who may find it informative.
Related reading
